CLARITY: Cladribine Tablets treating MS orally Giovannoni G et al. A placebo-controlled trial of Cladribine Tablets for patients with relapsing multiple sclerosis, N Engl J Med 362:416, February 4, 2010The CLARITY study designThe CLARITY study was a two – year , randomized, double – blind, placebo – controlled international study. It randomized 1,326 patients with relapsing-remitting MS according to the revised McDonald criteria. The study participants were randomly assigned to one of three treatment groups consisting of two different dose regimens of Cladribine Tablets or matching placebo tablets . Cladribine Tablets in two or four treatment courses given in the first year, with each course consisting of once daily administration for the four to five consecutive days , which means that the study involved patients.

EMD Serono initiated global filings for Cladribine Tablets mid-2009 and, to date, regulatory applications for Cladribine Tablets in approximately 40 countries submitted. Cladribine Tablets was granted its first marketing approval in July 2010, in Russia.. Cladribine TabletsEMD Serono ‘s oral formulation of cladribine is an investigational treatment for patients with relapsing multiple sclerosis . Thought to be involved molecule that can potentially interfere with the behavior and the proliferation of certain white blood cells, particularly lymphocytes, which are thought to be involved in the pathological process of MS.Over MedPredictMedPredict maintains a proprietary database of over 1,000 global medical pioneer of which 40+ cuisine at 30+ therapeutic categories. Balanced by the primary interviews with these visionaries, MedPredict publishes periodic reports to customers up-to-date with new developments and to keep activities of our competitors. The reports shall contain thought leaders reactions to recent publication and medical conferences as well as clinical, regulatory and marketing activities.